Clinical Trials · NCT07738276

Evaluation of the Efficacy and Safety of Tirzepatide, a Dual GLP-1/GIP Agonist, on Functional Capacity in Reduced Ejection Fraction Heart Failure Patients With Obesity

Name: Evaluation of the Efficacy and Safety of Tirzepatide, a Dual GLP-1/GIP Agonist, on Functional Capacity in Reduced Ejection Fraction Heart Failure Patients With Obesity
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

Not Yet RecruitingPhase 3Tirzepatide

Phase: Phase 3
Recruitment status: Not Yet Recruiting
Sponsor: Shahid Beheshti University of Medical Sciences
Enrollment: 60
Start date: Jul 2026
Locations: See registry
Primary endpoint: Change in 6-Minute Walk Distance

View Tirzepatide compound reference